Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery
- 1 August 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (7), 1400-1413
- https://doi.org/10.1038/bjp.2008.249
Abstract
The zebrafish is a well-established model organism used in developmental biology. In the last decade, this technology has been extended to the generation of high-value knowledge on safety risks of novel drugs. Indeed, the larval zebrafish appear to combine advantages of whole organism phenotypic assays and those (rapid production of results with minimal resource engagement) of in vitro high-throughput screening techniques. Thus, if appropriately evaluated, it can offer undeniable advantages in drug discovery for identification of target and off-target effects. Here, we review some applications of zebrafish to identify potential safety liabilities, particularly before lead/candidate selection. For instance, zebrafish cardiovascular system can be used to reveal decreases in heart rate and atrial-ventricular dissociation, which may signal human ether-a-go-go-related gene (hERG) channel blockade. Another main area of interest is the CNS, where zebrafish behavioural assays have been and are further being developed into screening platforms for assessment of locomotor activity, convulsant and proconvulsant liability, cognitive impairment, drug dependence potential and impaired visual and auditory functions. Zebrafish also offer interesting possibilities for evaluating effects on bone density and gastrointestinal function. Furthermore, available knowledge of the renal system in larval zebrafish can allow identification of potential safety issues of drug candidates on this often neglected area in early development platforms. Although additional validation is certainly needed, the zebrafish is emerging as a versatile in vivo animal model to identify off-target effects that need investigation and further clarification early in the drug discovery process to reduce the current, high degree of attrition in development.Keywords
This publication has 119 references indexed in Scilit:
- Evaluation of zebrafish embryos as a model for assessing inhibition of hERGJournal of Pharmacological and Toxicological Methods, 2008
- The teleost intervertebral region acts as a growth center of the centrum: In vivo visualization of osteoblasts and their progenitors in transgenic fishDevelopmental Dynamics, 2007
- In vivo imaging and genetic analysis link bacterial motility and symbiosis in the zebrafish gutProceedings of the National Academy of Sciences of the United States of America, 2007
- Distinct signals from the microbiota promote different aspects of zebrafish gut differentiationDevelopmental Biology, 2006
- In vivo drug discovery in the zebrafishNature Reviews Drug Discovery, 2005
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Pharmacogenetic Aspects of Drug-Induced Torsade de PointesDrug Safety, 2004
- Neomycin-Induced Hair Cell Death and Rapid Regeneration in the Lateral Line of Zebrafish ( Danio rerio )Journal of the Association for Research in Otolaryngology, 2003
- Clock mechanisms in zebrafishCell and tissue research, 2002
- Features of mono‐ and multinucleated bone resorbing cells of the zebrafish Danio rerio and their contribution to skeletal development, remodeling, and growthJournal of Morphology, 2001